Search
BioXcel Therapeutics Inc
BTAIAdd to Watchlist
1.390USD
+0.020+1.46%
Market hours （ET）Quotes delayed by 15 min
37.63MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of BioXcel Therapeutics Inc is 7.20, ranking 107 out of 157 in the Pharmaceuticals industry. The average price target is 12.00, with a high of 38.00 and a low of 1.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+807.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
BioXcel Therapeutics Inc
BTAI
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BioXcel Therapeutics Inc's expected revenue for the next quarter?
BioXcel Therapeutics Inc's expected revenue is 256.67K.
What is BioXcel Therapeutics Inc's price target?
Analysts forecast that BioXcel Therapeutics Inc's price target is USD 12.00, with the highest forecast at USD 38.00 and the lowest forecast at USD 1.00.
How have BioXcel Therapeutics IncBTAI's recent earnings per share performed?
The market expectation was USD -0.54, while BioXcel Therapeutics IncBTAI's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.51.
What is the analyst rating for BioXcel Therapeutics Inc?
Based on the ratings of BioXcel Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.